أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; dilute hydrochloric acid; water for injections; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: dilute hydrochloric acid; water for injections; trometamol; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 311.7 mg/ml - injection - excipient ingredients: trometamol; water for injections; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 498.72 mg/ml - injection, solution - excipient ingredients: water for injections; trometamol; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerized tomography. indications as at 6th july 2001: ultravist is indicated for all angiographic and urographic examinations and for contrast enhancements in computerised tomography. ultravist 240 is additionally indicated for lumbar myelography in adults.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; dilute hydrochloric acid; trometamol; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; sodium calcium edetate; trometamol; water for injections; sodium hydroxide - ultravist is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography.,ultravist 300 or 370 is indicated for use in contrast-enhanced mammography (cem) in adults, to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound).

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - iodine 240 mg in 1 ml - ultravist® injection is an iodinated contrast agent indicated for: *for information on the concentrations and doses for the pediatric population [see dosage and administration (2.3) and use in specific populations (8.4)]. risk summary there are no data on ultravist injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to 0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data). . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general p

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

bayer limited - iopromide - solution for injection - 300 milligram(s)/millilitre - watersoluble, nephrotropic, low osmolar x-ray contrast media; iopromide

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 498.72 mg/ml equivalent to 240 mg iodine - solution for infusion - 240 mg/ml - active: iopromide 498.72 mg/ml equivalent to 240 mg iodine excipient: hydrochloric acid as 10% solution sodium calcium edetate, hydrate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 623 mg/ml equivalent to iodine 300 mg/ml - solution for infusion - 300 mg/ml - active: iopromide 623 mg/ml equivalent to iodine 300 mg/ml excipient: hydrochloric acid as 10% solution sodium calcium edetate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.